project id: TCGA-KIRP; case submitter id: TCGA-2Z-A9JL; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.87; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.62; rna integrity number: 9.2; age at index: 47; days to birth: -17367; ethnicity: not hispanic or latino; gender: male; race: black or african american; vital status: Alive; year of birth: 1965; age at diagnosis: 17367; ajcc clinical m: M0; ajcc clinical n: N0; ajcc clinical stage: Stage I; ajcc clinical t: T1a; ajcc pathologic m: MX; ajcc pathologic n: NX; ajcc pathologic stage: Stage I; ajcc pathologic t: T1a; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1006.0; icd 10 code: C64.1; last known disease status: not reported; morphology: 8260/3; primary diagnosis: Papillary adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Kidney, NOS; synchronous malignancy: Yes; tissue or organ of origin: Kidney, NOS; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 678; days to sample procurement: 0; initial weight: 70.0; portion submitter id: TCGA-2Z-A9JL-01A-11; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 7.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 25.0; percent tumor cells: 75.0; percent tumor nuclei: 75.0;